STOCKHOLM, Feb. 14, 2020 /PRNewswire/ -- "We summarize
2019 and note that: RaySearch continues to develop at a rapid
pace. Order intake rose 30 percent and cash flow
adjusted for amortization of bank loans increased to SEK 72 M (-48). Product development proceeds
according to plan."
Johan Löf, CEO of RaySearch. Comments on page 2.
Fourth Quarter (October-December
2019)
- Order intake SEK 277.2 M
(294.9)
- Net sales SEK 234.5 M
(219.4)
- Operating profit SEK 22.5 M
(41.7)
- Profit after tax SEK 18.9 M
(32.8) and earnings per share before/after dilution SEK 0.55 (0.96)
- Cash flow SEK 7.8 M (56.8)
Twelve Months (January-December
2019)
- Order intake SEK 1,046.2 M
(805.2)
- Net sales SEK 741.6 M
(627.2)
- Operating profit SEK 68.2 M
(94.5)
- Profit after tax SEK 50.4 M
(78.5) and earnings per share before/after dilution SEK 1.47 (2.29)
- Cash flow SEK -3.4 M (1.8)
- Order backlog SEK 1,160.0 M
(828.0) at the end of the period
- The Board of Directors proposes that no dividend be paid for
2019
Significant Events During The Fourth Quarter
- The RayStation® treatment planning system was chosen by several
prominent cancer centers, including the Shanghai Proton and Heavy
Ion Center (SPHIC) in China, the
Yonsei Cancer Center in South
Korea, Universitätsklinikum Erlangen in Germany, the Royal Brisbane and Women's
Hospital in Australia, Providence
Health Care in Canada, and the
Mercy Hospital St. Louis and the Summa Health Cancer Institute in
the US.
- The RayCare® oncology information system was chosen by Yonsei
Cancer Center in South Korea and
Provision CARES Proton Therapy Orlando in the US.
- RaySearch received new regulatory clearance for RayStation in
China.
- In December, RayCare 3B* and
RayStation 9B* were released. These
are the latest versions of RaySearch's software, which now also
include support for the planning of chemotherapy and enhanced
machine learning
possibilities.
Significant Events After The End Of The Reporting
Period
- In February 2020, MD Anderson
Cancer Center in the US ordered additional RayStation licenses for
about SEK 40 million to replace its
existing treatment planning systems.
The information contained in this interim report is such that
RaySearch Laboratories AB (publ) is obliged to disclose under the
EU Market Abuse Regulation and the Swedish Securities Market Act.
The information was submitted for publication on February 14, 2020 at at 7:45 a.m. CET.
Teleconference In Connection With The Interim Report
CEO Johan Löf and CFO
Peter Thysell will present
RaySearch's year-end report for January-December 2019 at a teleconference to be held in
English on Friday, February 14, 2020
at 4:00 p.m. CET.
For login details to the teleconference, please register on:
http://emea.directeventreg.com/registration/6642347
About Raysearch
RaySearch Laboratories AB (publ) is a medical technology company
that develops innovative software solutions for improved cancer
treatment. The company develops and markets the RayStation
treatment planning system and RayCare oncology information system
to cancer centers all over the world and distributes the products
through licensing agreements with leading medical technology
companies. The company is also developing a new treatment control
system, RayCommand, which is expected to be launched at the
beginning of 2021. RaySearch's software is currently used by over
2,600 centers in more than 65 countries. The company was founded in
2000 as a spin-off from the Karolinska
Institute in Stockholm and
the share has been listed for trading on Nasdaq Stockholm since
2003.
More information about RaySearch is available at
www.raysearchlabs.com
For Further Information, Please Contact:
Johan Löf
President and CEO
Tel: +46-8-510-530-00
E-mail: johan.lof@raysearchlabs.com
Peter Thysell
CFO
Tel: +46-70-661-05-59
E-mail: peter.thysell@raysearchlabs.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/raysearch-laboratories/r/year-end-report-1-january---31-december-2019,c3035383
The following files are available for download:
https://mb.cision.com/Main/1102/3035383/1193901.pdf
|
The full report
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/year-end-report-1-january---31-december-2019-301005126.html
SOURCE RaySearch Laboratories